Emcure tax penalty orders totalling Rs 57.74 crore were disclosed by Emcure Pharmaceuticals Ltd in a BSE filing dated October 2, 2026. The company said it had received various orders from the Income-tax Department relating to ongoing litigation and was evaluating appropriate legal remedies, including an appeal before the Appellate Authority.

The aggregate penalty is Rs 57,73,96,732, according to the filing. The orders cover Financial Year 2014-15 to Financial Year 2020-21, corresponding to Assessment Year 2015-16 to Assessment Year 2021-22. The disclosed amount is the combined penalty across the orders, rather than a separately stated penalty for any one year.

Emcure submitted the disclosure to BSE and the National Stock Exchange under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The filing describes the development as regulatory orders concerning previously disclosed litigation.

Orders relate to an existing tax dispute

The annexure identifies the opposing party as the Deputy Commissioner of Income Tax, Central Circle 2 (1), Pune. It records December 27, 2023 as the date of initiation of the litigation or dispute.

The filing provides the following chronology and scope:

  • The ongoing litigation had been disclosed in the company's Integrated Governance Reports.
  • The latest report referred to in the filing covered the quarter ended June 30, 2026.
  • The current disclosure records receipt of penalty orders covering seven financial years, from FY2014-15 through FY2020-21.

The supplied annexure reports a single aggregate penalty figure. It does not provide a year-wise allocation of that amount or describe the underlying tax issues that led to the penalties.

Legal remedies under evaluation

Emcure said it was evaluating appropriate legal remedies, including filing an appeal before the Appellate Authority. The disclosure does not state that an appeal has already been filed or provide a timetable for that step.

Amruta Yangalwar, Company Secretary and Compliance Officer, signed the October 2 disclosure. Emcure is identified on BSE by scrip code 544210 and on NSE by the symbol EMCURE.